SynthesisAmerican journal of rhinology & allergy2021
Treatment of Sinonasal Teratocarcinosarcoma: A Systematic Review and Survival Analysis.
Synthesis in American journal of rhinology & allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- A Rare Presentation of Teratocarcinosarcoma as a Carinal Mass With Review of Literature.Respirology case reports · 2026Article
- Tomotherapy for sinonasal teratocarcinosarcoma with SMARCA4 deletion and CTNNB1 mutation: A case report and literature review.Precision radiation oncology · 2025Article
- Teratocarcinosarcoma of the nasal cavity: challenges in the clinico-pathologic perspectives.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Review
- Sinonasal teratocarcinosarcoma: a case report of a 41-year-old female.American journal of translational research · 2025Article
- Nonsurgical Management of Sinonasal Teratocarcinosarcoma With Chemoradiotherapy: A Case Report.Case reports in otolaryngology · 2025Article
- Sinonasal teratocarcinosarcoma involving the nasal cavity, unilateral paranasal sinuses, and intracranial invasion: A case report.World journal of clinical cases · 2024Article
- Article
- Sinonasal Malignancy Following Cranial Irradiation: A Scoping Review and Case Report of Sinonasal Teratocarcinosarcoma.Journal of neurological surgery reports · 2024Article
- Article
- Article
- Top 10 Basaloid Neoplasms of the Sinonasal Tract.Head and neck pathology · 2023Review
- Diagnostic and Treatment-Related Challenges in Sinonasal Teratocarcinosarcoma: A Report of Three Cases.Case reports in otolaryngology · 2023Article
- Teratocarcinosarcoma of the head and neck: Clinicopathologic review of a rare entity.Rare tumors · 2023Review
- Sinonasal teratocarcinosarcoma: a therapeutic dilemma.BMJ case reports · 2022Article
- Multimodality management of sinonasal teratocarcinosarcoma in a 76-year-old Alaska Native female during the COVID-19 pandemic.Clinical case reports · 2022Article
- Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: SWI/SNF-deficient Sinonasal Neoplasms: An Overview.Head and neck pathology · 2022Article
- Sinonasal teratocarcinosarcoma treated with surgery and proton beam therapy: clinical, histological aspects and differential diagnosis of a new case.Pathologica · 2021Article
- Endoscopic endonasal resection of sinonasal teratocarcinosarcoma with intracranial breakthrough: illustrative case.Journal of neurosurgery. Case lessons · 2021Article
- Aggressive Craniospinal Recurrence of aCase reports in oncologyArticle
- Dissenting an Uncommon Diagnosis at Unusual Origin: A Case Report of Teratocarcinosarcoma of Sinonasal Cavity - A Rare Malignancy.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSinonasal teratocarcinosarcoma (SNTCS) is a rare malignancy of the anterior skull base with only 127 cases described in the English literature. Given the rarity of this tumor, new cases and analysis of published reports may assist in future management of SNTCS.
objectives1) Describe findings from a systematic review of all available literature for malignant SNTCS including the clinical presentation, treatment modalities and outcomes. 2) Present two new cases of this rare anterior skull base tumor. 3) Compare treatment outcomes with respect to recurrence and mortality.
methodsA systematic review of all English literature available in 2 comprehensive databases was conducted by two independent reviewers using PRISMA guidelines. 85 publications were identified. Each case was reviewed for demographics, treatment and survival, and aggregate treatment outcomes were compared using Kaplan-Meier analysis.
resultsA total of 64 articles meeting inclusion criteria were reported in the literature between 1977-2018. This represented a total of 127 patients, with a strong male predominance (83%) and mean age of 50 years (range 10-82). Mean follow-up was 21 months. Recurrence rate was 38%, with mean survival at 2 years of 55%. Almost all patients underwent surgery as a primary treatment modality (90%). The majority of cases were treated with multimodal therapy, with 55% receiving surgery and radiation and 20% receiving surgery with adjuvant chemoradiation. Kaplan-Meier analysis demonstrated a significant survival advantage for patients treated with combined therapy compared to surgery alone (p < 0.001) but did not show differences in recurrence (p = 0.085).
conclusionTwo-year survival rates for SNTCS are 55%. Multimodality treatment outcomes appear to be superior to surgery alone based on the published data of this rare skull base tumor, although heterogeneity of treatment methods and reporting bias limits the generalizability of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.